Stocks

Headlines

Coherus Biosciences Reports Q4 Loss of $50.7 Million

Coherus Biosciences faces challenges as it reports a fourth-quarter loss of $50.7 million, reflecting a decline in both revenue and EPS. Investors will be concerned about these figures impacting stock prices.

Date: 
AI Rating:   4

Earnings Per Share (EPS): Coherus reported an EPS of -$0.44, an improvement over last year's -$0.71. While still negative, this shows some progress, which could be seen as a positive sign in regards to managing losses.

Revenue Growth: The company's revenue for the period fell significantly by 40.8%, dropping to $54.14 million from $91.52 million last year. This sharp decline raises concerns about future sales potential and overall market performance.

Overall Assessment: The negative earnings and declining revenue provide a clear indication of challenges that could weigh heavily on Coherus Biosciences' stock prices. Investors might remain cautious following this report, affecting future investment and stock attractiveness.

Stocks:  CHRS